Characterization of low-density granulocytes in COVID-19.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
07
05
2021
accepted:
17
06
2021
revised:
16
07
2021
pubmed:
7
7
2021
medline:
10
8
2021
entrez:
6
7
2021
Statut:
epublish
Résumé
Severe COVID-19 is characterized by extensive pulmonary complications, to which host immune responses are believed to play a role. As the major arm of innate immunity, neutrophils are one of the first cells recruited to the site of infection where their excessive activation can contribute to lung pathology. Low-density granulocytes (LDGs) are circulating neutrophils, whose numbers increase in some autoimmune diseases and cancer, but are poorly characterized in acute viral infections. Using flow cytometry, we detected a significant increase of LDGs in the blood of acute COVID-19 patients, compared to healthy controls. Based on their surface marker expression, COVID-19-related LDGs exhibit four different populations, which display distinctive stages of granulocytic development and most likely reflect emergency myelopoiesis. Moreover, COVID-19 LDGs show a link with an elevated recruitment and activation of neutrophils. Functional assays demonstrated the immunosuppressive capacities of these cells, which might contribute to impaired lymphocyte responses during acute disease. Taken together, our data confirms a significant granulocyte activation during COVID-19 and suggests that granulocytes of lower density play a role in disease progression.
Identifiants
pubmed: 34228753
doi: 10.1371/journal.ppat.1009721
pii: PPATHOGENS-D-21-00905
pmc: PMC8284631
doi:
Substances chimiques
OLR1 protein, human
0
Scavenger Receptors, Class E
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009721Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sci Rep. 2021 Mar 1;11(1):4904
pubmed: 33649400
J Infect Dis. 2021 Mar 29;223(6):933-944
pubmed: 33280009
Trends Immunol. 2019 Jul;40(7):584-597
pubmed: 31153737
J Immunol Methods. 1999 Dec 17;232(1-2):191-200
pubmed: 10618520
Front Immunol. 2017 May 12;8:550
pubmed: 28553293
Cells. 2020 Jun 02;9(6):
pubmed: 32498376
Arch Immunol Ther Exp (Warsz). 2018 Feb;66(1):21-30
pubmed: 28560557
Cytometry. 2000 Dec 15;42(6):371-8
pubmed: 11135291
J Clin Invest. 2020 Nov 2;130(11):6151-6157
pubmed: 32759504
J Immunol. 2019 Jan 1;202(1):207-217
pubmed: 30504419
Immunity. 2020 Aug 18;53(2):303-318.e5
pubmed: 32579887
Blood Cells Mol Dis. 2002 Mar-Apr;28(2):260-74
pubmed: 12064921
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Nat Rev Immunol. 2002 Dec;2(12):977-82
pubmed: 12461570
Virus Res. 2013 Jan;171(1):1-7
pubmed: 23178588
Am J Respir Crit Care Med. 2015 Feb 15;191(4):455-63
pubmed: 25485813
J Infect. 2020 Jul;81(1):e6-e12
pubmed: 32283162
J Immunol. 2016 Sep 1;197(5):1989-99
pubmed: 27481851
Cancer Immunol Immunother. 2019 Apr;68(4):687-697
pubmed: 30684003
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620933508
pubmed: 32539627
Nat Commun. 2021 Mar 5;12(1):1428
pubmed: 33674591
Arch Dis Child. 2003 Jun;88(6):529-31
pubmed: 12765925
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
J Immunol. 2019 Jan 1;202(1):3-4
pubmed: 30587567
J Leukoc Biol. 2021 Jan;109(1):99-114
pubmed: 33617030
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12989
pubmed: 29956819
J Immunol. 2010 Mar 15;184(6):3284-97
pubmed: 20164424
Immunity. 2020 Dec 15;53(6):1296-1314.e9
pubmed: 33296687
Blood Adv. 2019 Nov 26;3(22):3562-3574
pubmed: 31738831
Blood Adv. 2021 Mar 9;5(5):1164-1177
pubmed: 33635335
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Immunol. 2011 Jul 1;187(1):538-52
pubmed: 21613614
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Microbiol Mol Biol Rev. 2018 Feb 7;82(1):
pubmed: 29436479
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
J Leukoc Biol. 2020 May;107(5):809-818
pubmed: 32170882
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Br J Haematol. 2000 Dec;111(3):934-42
pubmed: 11122158
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Nat Rev Immunol. 2014 May;14(5):302-14
pubmed: 24751955
Respirology. 2016 Jan;21(1):172-9
pubmed: 26477783
Nat Med. 2009 Jun;15(6):623-5
pubmed: 19448636
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870